New cell therapy trial targets Tough-to-Treat blood cancer

NCT ID NCT06307054

Recruiting now Disease control Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new cell therapy for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to better target the cancer, and then infuse them back. The main goals are to check the safety of this approach and see if it shows any early signs of fighting the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY AML are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Shanghai General Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200080, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

REFRACTORY AML RELAPSED ADULT AML